by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
by Elena Iemma | Mar 1, 2025 | Blog
The EpiVax team is dedicated to advancing the science of immunogenicity assessment and streamlining the preclinical drug development process for our partners worldwide. This month, we’re excited to share several updates with you, including new and updated in silico...
by Elena Iemma | Mar 29, 2024 | News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Mar 15, 2024 | Blog
Tregitopes by Another Name? OK, sometimes, I am late to the party. Maybe … allowing ideas, like parties, to mature, means getting there at exactly the right time. That just happened with this article and I’d like to share it with you. It’s...
by Elena Iemma | Dec 23, 2023 | Blog
FDA Request for “Integrated Summary of Immunogenicity” So much news to share! EpiVax Delivers! As promised, EpiVax 2.0 will be arriving in 2024, our 26th year, along with new team members and new plans to expand the range of services offered. Here...
